EGFR and lung cancer: On the other hand, EGFR mutant lung cancer is more immunologically “cold,” and while treatment with higher-generation targeted therapy (e.g., Osimertinib) is associated with greater overall survival and improved prognosis, immune checkpoint blockade responsiveness by such tumors is low (85).